ASTELLAS PHARMA EUROPE LTD.

Major pharmaceutical companies including AstraZeneca, Novartis, and Astellas are defending patents for blockbuster drugs like Lynparza, Entresto, and Xtandi against generic manufacturers in early 2025.

Schrödinger has terminated development of its CDC7 inhibitor SGR-2921 after two patient deaths in a Phase I trial for relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes.

FibroGen has reached agreement with the FDA on key design elements for a pivotal Phase 3 trial of roxadustat in lower-risk myelodysplastic syndrome patients with high transfusion burden.

The STAMPEDE trial found that adding metformin to standard care for 1,874 non-diabetic men with metastatic prostate cancer did not significantly improve overall survival (HR 0.91, 95% CI: 0.80-1.03, P = 0.15).

Astellas, one of Japan's largest life sciences companies, announced a €129 million investment in its Irish operations over the next three years, focusing on development, sustainability, and research initiatives.

Major pharmaceutical and biotech companies including Pfizer, Johnson & Johnson, Fate Therapeutics, and Generation Bio are implementing workforce reductions as part of industry-wide financial restructuring efforts.

The District Court The Hague dismissed nullity suits from Accord Healthcare and Sandoz against Xtandi's basic patent EP 1 893 196 and its Dutch SPC, maintaining protection until June 2028.

The 15th World ADC San Diego conference (November 4-7, 2024) represents the industry's largest and most comprehensive ADC-focused forum, featuring 120+ speakers across six development tracks.

Royalty Pharma shareholders have overwhelmingly approved the acquisition of its external manager, with 99.9% voting in favor at the company's 2025 Annual General Meeting.

Dyno Therapeutics has launched three breakthrough AAV capsid vectors targeting the eye, muscle, and central nervous system, each demonstrating significant improvements over conventional AAV vectors in non-human primates.